ConductScience.org, home

Paper42577451

Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer.

Zhou H and 5 others. Front Immunol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer. Papers, record 42577451. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42577451

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Identification of LILRB4 as a regulator of M2c macrophages and a potential immunotherapeutic target in ovarian cancer.
PubMed
Journal
Front Immunol
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhou HHuijuan
2Zhang QQing
3Yin BBo
4Han LLingfei
5Huang XXiaohui
6Li SShuangdi

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Ovarian NeoplasmsMajor topic
Receptors, ImmunologicMajor topic
MacrophagesMajor topic
Membrane GlycoproteinsMajor topic
Tumor-Associated MacrophagesMajor topic
Female
Humans
Animals
Cell Line, Tumor
Tumor Microenvironment
Mice
Immunotherapy
Gene Expression Regulation, Neoplastic
Cell Proliferation
Signal Transduction

Source PubMed

Download CSV of topics

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139569201Mechanisms and treatment of atherosclerosis: focus on macrophages.Front Immunol2024https://conductscience.org/library/papers/39569201PubMed
238813706LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.Haematologica2024https://conductscience.org/library/papers/38813706PubMed
339842553LILRB4 as a novel immunotherapeutic target for multiple diseases.Biochem Pharmacol2025https://conductscience.org/library/papers/39842553PubMed
437290427Prognostic impact of LILRB4 expression on tumor-infiltrating cells in resected non-small cell lung cancer.Thorac Cancer2023https://conductscience.org/library/papers/37290427PubMed
540690248Ovarian Cancer: A Review.JAMA2025https://conductscience.org/library/papers/40690248PubMed
640048761LILRB4 specific overexpression in myeloid cells promotes tumor progression and immunosuppression in mouse models.Biochem Biophys Res Commun2025https://conductscience.org/library/papers/40048761PubMed
735174213Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer.Front Mol Biosci2022https://conductscience.org/library/papers/35174213PubMed
839232212Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/39232212PubMed
925756512PTEN inhibits macrophage polarization from M1 to M2 through CCL2 and VEGF-A reduction and NHERF-1 synergism.Cancer Biol Ther2015https://conductscience.org/library/papers/25756512PubMed
1040349571Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review.Cancer Treat Rev2025https://conductscience.org/library/papers/40349571PubMed
1135447518Multifunctional "ball-rod" Janus nanoparticles boosting Fenton reaction for ferroptosis therapy of non-small cell lung cancer.J Colloid Interface Sci2022https://conductscience.org/library/papers/35447518PubMed
1241613134SLC40A1-mediated positive feedback loop with M1 macrophages suppresses epithelial ovarian cancer progression.Front Immunol2025https://conductscience.org/library/papers/41613134PubMed
1341089676Reprogramming the immune microenvironment in lung cancer.Front Immunol2025https://conductscience.org/library/papers/41089676PubMed
1439975548Polymorphisms in immunosuppression-related genes are associated with AML.Front Immunol2025https://conductscience.org/library/papers/39975548PubMed
1533777950CXCL11 Correlates With Antitumor Immunity and an Improved Prognosis in Colon Cancer.Front Cell Dev Biol2021https://conductscience.org/library/papers/33777950PubMed
1626707054Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.Lancet2016https://conductscience.org/library/papers/26707054PubMed
1739896800Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies.Front Immunol2024https://conductscience.org/library/papers/39896800PubMed
1834586722Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway.Clin Transl Med2021https://conductscience.org/library/papers/34586722PubMed
1924936477Tumor-associated macrophages contribute to tumor progression in ovarian cancer.Front Oncol2014https://conductscience.org/library/papers/24936477PubMed
2040777010Transglutaminase 2 regulates ovarian cancer metastasis by modulating the immune microenvironment.Front Immunol2025https://conductscience.org/library/papers/40777010PubMed

See all 50 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.

PMIDTitleJournalYearIn Papers
42959057Regulatory mechanism of M2d tumor-associated macrophage-derived exosomal apolipoprotein E on platinum resistance in ovarian cancer.Front Oncol2026https://conductscience.org/library/papers/42959057

Source PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CCL56352PubTator's text mininghttps://conductscience.org/library/genes/6352NCBI Gene
LILRB411006PubTator's text mininghttps://conductscience.org/library/genes/11006NCBI Gene
RELA5970PubTator's text mininghttps://conductscience.org/library/genes/5970NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42577451

GET https://conductscience.org/api/papers/v1/42577451/references?page=2